Europe Suture Market Report

Europe Suture Market Size

The Europe suture market was valued at USD 1.44 billion in 2025, is estimated to reach USD 1.52 billion in 2026, and is projected to reach USD 5.68 billion by 2034, growing at a CAGR of 5.68% from 2026 to 2034.

The suture is a clinical use of medical devices designed to approximate and secure tissues during surgical interventions or wound closure. These include absorbable and non-absorbable sutures made from natural materials like silk or synthetic polymers, such as polyglactin and polypropylene, delivered in various forms including monofilament, braided,ded, and barbed configurations. Sutures are classified as Class IIa or higher medical devices under the EU Medical Devices Regulation,tion requiring rigorous conformity assessment for safety, biocompatibility, and performance. According to the European Centre for Disease Prevention and Control, over 28 million surgical procedures are performed annually across the European Union, with an average of 3 to 5 sutures used per intervention. As per Eurostat, more than 19 million hospital discharges involving surgery were recorded in 2023, reflecting sustained procedural volume.

MARKET DRIVERS

Rising Volume of Surgical Procedures Driven by Aging Population and Chronic Diseases

The increasing burden of age-related and chronic conditions for surgical interventions is majorly propelling the growth of Europe's suture market. According to Eurostat, 22.3% of the EU population was aged 65 or older in 2024, a figure projected to reach 29% by 2035. This demographic shift correlates with a higher incidence of cardiovascular diseases, cancer, er and orthopedic degenerationall requiring surgical management. The European Society of Cardiology reports that over 1.2 million coronary artery bypass grafting procedures were performed in the EU in 2023 alone, each utilizing multiple high tensile strength sutures. Similarly, the European Cancer Organisation notes that 3.8 million new cancer cases are diagnosed annually necessitate tumor resection, often involving complex soft tissue closure. This procedural growth creates consistent demand for reliable sterile and biocompatible sutures across public and private healthcare settings,s reinforcing market stability and innovation incentives.

Adoption of Minimally Invasive and Robotic-Assisted Surgeries

The rapid integration of laparoscopic, ic robotic, and endoscopic techniquesacross European operating rooms is driving demand for specialized suture technologies engineered for precision and compatibility with advanced instrumentation. The adoption of minimally invasive surgeries is escalating the growth of Europe's suture market. According to the European Association of Endoscopic Surgery, over 65% of general surgeries in Western Europe were performed using minimally invasive approaches in 2024, up from 48% in 2020. These procedures require fine caliber sutures with enhanced knot security, reduced tissue drag, ag and compatibility with robotic needle drivers. The da Vinci Surgical System, alone, was used in over 320,000 procedures across the EU in 2023 as per Intuitive Surgical’s European deployment data, necessitating proprietary suture cartridges and preloadedneedles. Hospitals in Sweden, the Netherlands, and Germanylead adoption with robotic surgery programs covering urology g,, gynecology, and colorectal specialties. Additionally, the European Board of Surgical Qualification now includes minimally invasive suturing proficiency in certification requirements,s ensuring sustained clinician training and product uptake. This technological evolution shifts preference toward high-performance engineered sutures that support smaller incisions, faster recovery, and reduced complication rates.

MARKET RESTRAINTS

Stringent Regulatory Requirements Under the EU Medical Devices Regulation

The implementation of the EU Medical Devices Regulation has significantly increased compliance burdens for suture manufacturers, particularly small and medium enterprises lacking dedicated regulatory infrastructure. The stringent regulatory requirement under the EU medical devices regulations is hampering the growth of Europe's suture market. According to the European Commission, over 70% of legacy suture products underwent re-certification between 2021 and 2024, requiring extensive clinical evaluation,n technical documentation, and post-market surveillance plans. The regulation mandates unique device identification UDI implementation,tion stricter scrutiny of raw material sourcing, and comprehensive risk management files. As per the European Association of Medical Device Manufacturers, the average time to obtain CE certification for a new suture type now exceeds 16 months compared to 10 months under the previous directive. National competent authorities like Germany’s BfArM conduct unannounced audits focusing on sterilization validation and supplier traceability. These heightened requirements increase development costs and delay market entry, disproportionately affecting niche innovators and reducing product diversification, ty particularly in cost-sensitive segments, such as basic absorbable sutures used in public hospitals.

Intense Price Pressure from Public Procurement and Tender Systems

Public healthcare systems across Europe exert significant downward pressure on suture pricing through centralized tendering and reference pricing mechanisms aimed at containing expenditure. According to the European Observatory on Health Systems and Policies, 23 EU countries utilize national or regional tenders for surgical consumables, with price often being the decisive award criterion. Germany’s DRG system bundles suture costs into procedure reimbursements, ts discouraging premium adoption unless a clear clinical benefit is demonstrated. This environment favors large multinational suppliers with economies of scale while marginalizing smaller players unable to compete on cost alone. Furthermore, hospitals increasingly consolidate vendors to reduce inventory complexity, limiting opportunities for differentiated but higher-priced innovations such as antimicrobial or barbed sutures. These financial constraints stifle investment in next-generation products and restrict access to advanced wound closure technologies, particularly in Southern and Eastern Europe.

MARKET OPPORTUNITIES

Integration of Antimicrobial and Bioactive Coatings to Reduce Surgical Site Infections

The growing emphasis on patient safety and hospital-acquired infection control for advanced suture technologies embedded with antimicrobial or bioactive agents is creating new opportunities for the growth of Europe's suture market. According to the European Centre for Disease Prevention and Control, surgical site infections affect 2.5 to 5% of all surgical patients in the EU, resulting in prolonged hospitalization and additional costs exceeding 1.5 billion euros annually. In response, national health agencies are updating guidelines to encourage preventive measures, where the UK’s National Institute for Health and Care Excellence now recommends antimicrobial sutures for clean contaminated procedures. Triclosan-coated polyglactin sutures have demonstrated a 30% reduction in SSIs in meta-analyses published by the Cochrane Collaboration in 2024. Companies like Ethicon and B. Braun have launched silver ion and chlorhexidine impregnated variants, gaining traction in German and Dutch hospitals participating in infection reduction initiatives. As per the European Wound Management Association, bioactive sutures that release growth factors or anti-inflammatory agents are entering clinical trials,s offering potential for enhanced healing in diabetic and elderly patients.

Expansion of Outpatient and Ambulatory Surgery Centers

The structural shift towards same-day surgery and ambulatory care models across Europe creates demand for sutures that support rapid healing, minimal follow-up, and patient self-management, which is anticipated to leverage the growth ofEurope'se suture market. According to the European Agency for Specialised Medical Care, over 45% of elective surgeries in the EU were performed in outpatient settings in 2024, up from 32% in 20,19 driven by cost efficiency and patient preference. These proceduresrerangerom hernia repairs to cosmetic surgeries,ries favor absorbable monofilament or barbed sutures that eliminate suture removal visits and reduce clinic workload. Countries like Sweden, Denmark, and the Netherlands lead this transition with over 60% of minor surgeries conducted in freestanding ambulatory centers, as per national health statistics. Additionally, patient-reported outcome measures now influence reimbursement decisions, incentivizing clinics to adopt technologies that minimize pain scarring and recovery time. This trend supports innovation in user-friendly suture designs that enhance both clinical efficiency and patient experience in decentralized care environments.

MARKET CHALLENGES

Environmental and Sustainability Concerns Regarding Single-Use Medical Waste

The widespread use of single-use sutures contributes to the growing volume of medical plastic waste in Europe, raising sustainability concerns under the EU’s Green Deal and Circular Economy Action Plan. The environmental and sustainability concerns regarding single-use medical waste are quite challenging for the growth of Europe suture market. France’s Anti Waste Law for a Circular Economy, enacted in 2023, requires medical device manufacturers to implement eco-design principles and take back schemes by 2,026 a mandate that poses logistical and financial challenges for suture producers. As per a 2025study by the Technical University of Berlin, conventional suture packaging contains mixed plastics with less than 10% recyclability under current municipal systems. While reusable alternatives exist, sterility and cross-contamination risks limit their feasibility in most surgical contexts. Without standardized guidelines for sustainable packaging or incentives for circular business models, the industry faces reputational and regulatory risks that could impede long-term social license to operate, te particularly in environmentally conscious Northern European markets.

Shortage of Skilled Surgical Personnel and Standardization of Techniques

A persistent deficit in trained surgical staff affects consistent suture selection and technique application in rural and underserved regions, which additionally limits the growth of the European suture market. According to the European Union of Medical Specialists, over 15% of surgical positions in public hospitals remained unfilled in 2024, with acute shortages in Eastern member states. This workforce gap leads to variability in wound closure practices, with junior clinicians often defaulting to familiar or institution-stocked suture types rather than optimal choices for specific tissue layers. Additionally, the lack of standardized training in advanced suturing, such as barbed or knotless techniques, limits the adoption of innovative products even when available. The European Board of Surgical Qualification notes that only 38% of residency programs include formal modules on modern suture technologies as of 2024. This knowledge gap reduces clinical differentiation and slows market uptake of value-added sutures that require specific handling protocols. Until structured education and simulation-based training become universal, the full therapeutic potential of next-generation suture systems will remain underutilized across much of the European surgical landscape.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Type Insights

The suture threads segment was the largest by holding a dominant share of the European suture market in 2025 due to their universal applicability across surgical specialties cost effectiveness and well-established clinical protocols. According to the European Centre for Disease Prevention and Control, over 28 million surgical procedures performed annually in the EU relyprimarily on traditional suture threads for tissue approximation w, with an average of 4 to 6 sutures used per operation. These products are available in a wide range of absorbable and non-absorbable variants, allowing surgeons to select based on tissue type,e healing time, and infection risk. National health systems favor suture threads due to predictable pricing and compatibility with existing inventory management systems. As per Germany’s Federal Joint Committee, suture threads account for over 95% of wound closure consumables reimbursed under statutory health insurance. Additionally, their simplicity reduces training burden in high-volume settings such as emergency departments and outpatient clinics.

The automated suturing devices segment is likely to witness the fastest CAGR of 13.4% throughout the forecast period, owing to the rising adoption of robotic and minimally invasive surgeries, which demand precision, consistency, and reduced operative time. According to the European Association of Endoscopic Surgery,y robotic-assisted procedures grew by 22% annually between 2022 and 2024, with over 350,000 cases performed in 2024alone requiring specialized suturing tools. Devices like the da Vinci SureForm and Medtronic’s Signia Stapling System integrate pre-loaded needles and motorized deployment e, enabling accurate placement in confined anatomical spaces. Furthermore, the European Board of Surgical Qualification has incorporated robotic suturing proficiency into advanced certification pathways, encouraging hospital investment. As per the Technical University of Munich, automated systems reduce suture-related complications in complex reconstructions, ns enhancing patient outcomes and justifying premium reimbursement in value-based care models.

By Type Insights

The multifilament sutures segment was accounted in holding a significant share of tEuropeanope suture market in 2025with their superior knot security, handling ease,e and widespread use in cardiovascular and general surgery. Composed of braided or twisted fibers, these sutures offer high tensile strength and flexibility, making them ideal for tissues under mechanical stress, such as blood vessels and fascia. According to the European Society of Cardiology, over 85% of coronary artery bypass grafting procedures in 2025utilized braided polyester or silk sutures due to their secure knot retention and minimal slippage. Additionally, their textured surface facilitates better grip during manual tying, which is a key advantage in open surgeries prevalent in Southern and Eastern Europe. Despite higher infection risk compared to monofilament antimicrobial coatings, such as triclosan, clinical studies have mitigated this concern, with clinical studies showing a 30% reduction in surgical site infections as per the Cochrane Collaboration 2025review, reinforcing their continued preference among experienced surgeons.

The monofilament sutures segment is anticipated to grow at the fastest CAGR of 11.8% during the forecast period, with its smooth surface, low tissue reactivity, and suitability for delicate procedures such as ophthalmic plastic and pediatric surgeries. According to the European Society of Ophthalmology, over 90% of cataract and corneal transplant procedures in 2025used monofilament nylon or polypropylene sutures to minimize inflammation and scarring. The rise of minimally invasive techniques further favors monofilaments as their single-strand design reduces drag through trocar ports and causes less trauma in laparoscopic closures. In Germany and Switzerland, national infection control programs actively promote monofilament use in clean contaminated surgeries due to lower bacterial adherence and lower incidence of wound infections in abdominal procedures using monofilaments versus braided alternatives. Additionally, innovations in polymer chemistry have improved knot security, addressing historical limitations. As per the European Wound Management Association, newer monofilaments with memory retention and enhanced elasticity are gaining traction in cosmetic surgery,y where fine aesthetic outcomes are paramount.

By Application Insights

The general surgery segment was the largest by holding 34.2% oe Europe's suture market share in 2025due to the high volume of abdominal, gastrointestinal, and hernia repair procedures performed annually across public and private hospitals. According to Eurostat, over 9.2 million general surgical interventions were recorded in the EU in 2023, with hernia repairs alone exceeding 1.5 million cases. These procedures require robust multifilament absorbable sutures for fascial closure and non-absorbable variants for skin approximation, ensuring long term integrity and low recurrence rates. National health systems prioriticost-effectiveive yet reliable solutions, and polypropylene sutures are included in mandatory procurement lists for all public hospitals. Additionally, the prevalence of obesity and aging populations drives demand for complex abdominal wall reconstructions, often involving mesh fixation with specialized barbed sutures. The European Hernia Society’s 2025guidelines reinforce suture-based mesh anchoring as a gold standard, rd reducing chronic pain compared to tack fixation. This procedural volume, clinical standardization, and reimbursement support sustain general surgery as the cornerstone of suture consumption in Europe.

The cosmetic and plastic surgery segment is growing at an anticipated CAGR of 12.9% throughout the forecast period, owing to the rising demand for aesthetic procedures, body contouring, and reconstructive surgeries post oncology or trauma. According to the European Society of Aesthetic Surgery, over 3.1 million cosmetic procedures were performed in the EU in 2024, with facelifts, breast augmentations, and liposuction leading the growth. These interventions prioritize fine monofilament and barbed sutures that minimize scarring, ensure precise tissue alignment,t and eliminate suture removal visits. Countries like Spain, Italy, and the UK report double-digit annual growth in outpatient aesthetic centers, as per national medical board data. Additionally, the integration of regenerative techniques, such as fat grafting and PRP therapy, requires specialized sutures that support vascular ingrowth without inflammatory response. As per the University of Copenhagen, a 2025study demonstrated that barbed PDO sutures improved skin tightening outcomes in non-surgical lifts by 35%.

By End User Insights

The hospitals segment accounted for a significant share of Europe's suture market in 2025due to their role as primary sites for complex inpatient surgeries, emergency care, nd teaching. According to the European Hospital Association, over 22 million inpatient surgical procedures were performed in EU hospitals in 2023, spanning cardiovascular, orthopedic,c and oncological specialties that demand high volumes of diverse suture types. Centralized procurement through national health service frameworks ensures bulk purchasing of standardized suture kits, reducing unit costs. As per Germany’s DRG system, suture expenses are bundled into procedure reimbursements incentivizingng efficiency without compromising quality. Additionally, hospitals serve as training grounds where residents learn suture selection and technique under supervision, enforcing institutional preferences for trusted brands. The presence of sterile processing departments also supports the use of reusable needle holders and trays compatible with disposable sutures.

The ambulatory surgical centers segment is likely to grow at the fastest CAGR of 14.2% throughout the forecast period, with the shift toward same-day surgery for hernia repairs, cataract extractions, cosmetic procedures, es, a nd minor orthopedic interventions. These centers prioritize efficiency,cy rapid turnover, er and patient satisfaction, favoring absorbable monofilament and barbed sutures that eliminate suture removal visits and reduce post-operative visits. In the Netherlands and Denmark, over 70% of ASCs now use pre-sterilized single-use suture kits to streamline workflows and ensure compliance with infection control standards. As per a study report, ASCs performing cosmetic and dermatologic procedures show the highest suture innovation uptake, including antimicrobial and fast-absorbing variants. This trend aligns with Europe’s broader healthcare strategy to reduce hospital congestion and enhance patient convenience, driving sustained growth in decentralized surgical settings.

COUNTRY LEVEL ANALYSIS

Germany Suture Market Analysis

Germany was the largest contributor to Europe suture market by holding 23.3% of the share in 2024, with its high surgical volumea vanced healthcare infrastructure, re and stringent quality standards. According to the Federal Statistical Office, over 6.8 million inpatient and 4.2 million outpatient surgeries were performed in 2023, reflecting robust procedural activity across public and private facilities. The country’s statutory health insurance system fully reimburses medically necessary sutures with clear guidelines favoring evidence-based products. Germany is also a hub for surgical innovation; institutions likeCharitée Berlin and Heidelberg University Hospital lead in robotic and minimally invasive techniques requiring specialized suture technologies. As per the German Medical Devices Registry, over 95% of suture products sold in the country comply with the EU Medical Devices Regulation, including UDI implementation anpost-marketet surveillance. The presence of global manufacturers like B. Braun and regional distributors ensures a consistent supply and clinical education.

United Kingdom Suture Market Analysis

The United Kingdom was ranked second by capturing 16.3% of Europe's market share in 2024, with centralized procurement through the National Health Service and a strong emphasis on infection control. According to the NHS, England, over 10 million surgical procedures were conducted in 2023, with antimicrobial sutures mandated for clean contaminated cases under NICE guidelines. The NHS Supply Chain regularly tenders for suture products, distributing millions of units annually to hospitals and ASCs,s ensuring price stability and quality assurance. Additionally, the Royal College of Surgeons promotes standardized suture training across residency programs, ms enhancing product consistency.

France Suture Market Analysis

France suture market growth is expected to have a significant growth opportunity in the coming years, due to universal healthcare coverage, high surgical densi, ty, and proactive infection prevention policies. According to the French National Authority for Health, over 8.5 million surgeries were performed in 2023, with hernia and bariatric procedures showing the fastest growth. The Haute Autorité de Santé recommends specific suture types for each surgical specialty and mandates antimicrobial variants for abdominal closures. France’s public hospitals operate under strict procurement rules that prioritize cost per outcome,e leading long-termerm contracts with major suppliers. As per the French Agency for Health Product Safety, over 1.2 million suture adverse event reports were reviewed in 2024, reinforcing vigilance and quality control. Additionally, France invests in surgical robotics with over 120 da Vinci systems installed nationwide, increasing demand for compatible automated suturing devices. This combination of clinical rig, regulatory oversight, and technological adoption shapes a dynamic and quality-conscious market environment.

Italy Suture Market Analysis

Italy suture market growth is expected to grow with the high volumes of general and cosmetic surgery and strong regional healthcare autonomy. According to a study, over 7 million surgical interventions were recorded in 2023, with significant activity in Lombar,dy La,zio and Campania regions. Italy has one of Europe’s highest rates of aesthetic procedures; the Italian Society of Aesthetic Surgery reported 420,000 interventions in 2024, driving demand for fine monofilament and barbed sutures. While national reimbursement exist implementation varies by region, though most include suture costs in DRG bundles. The Ministry of Health funds hospital modernization programs that upgrade operating rooms with minimally invasive capabilities, increasing uptake of advanced sutures. This grassroots surgical culturee combined with aesthetic demand, creates a resilient and diversified market.

Netherlands Suture Market Analysis

The Netherlands suture market growth is driven by efficient healthcare delivery, high outpatient surgery rates, and early adoption of innovative suture technologies. According to the Dutch Health Care Inspectorate, over 3.2 million procedures were performed in 2023, with 65% in an ambulatory setting,,s reflecting a strong shift towards same-day care. The country’s integrated care networks standardize suture protocols across hospitals and ASCs, favoring evidence-based products with proven infection reduction. As per the Netherlands Federation of University Medical Centers, antimicrobial sutures are routinely used in colorectal and gynecological surgeries, reducing SSIs. The Netherlands also leads in sustainability initiatives, and hospitals participate in circular economy pilots for medical device packaging, influencing suture supplier practices. Additionally, Dutch surgeons actively contribute to European surgical guidelines promoting best practices in suture selection.

COMPETITIVE LANDSCAPE

The European suture market features intense competition among multinational medical device leaders, regional specialists, and emerging innovators, each vying for differentiation through clinical evidence, technological advancement, and regulatory excellence. Global players like Johnson & Johnson,n B. Braun, and Medtronic dominate through extensive portfolios, robust distribution networks, and deep hospital relationships, while maintaining strong compliance with the EU Medical Devices Regulation. Regional manufacturers compete on cost and local service, particularly in Southern and Eastern Europe, pe where price sensitivity influences procurement decisions. The competitive landscape is increasingly shaped by value-based healthcare models that reward outcomes such as reduced surgical site infections and shorter hospital stays, ays favoring premium sutures with proven clinical benefits. Innovation in barbed absorbable and antimicrobial technologies creates differentiation but faces barriers from public tender systems that prioritize price over performance. Success requires balancing scientific credibility, regulatory agility, and strategic engagement with surgeons, educators, and payers across diverse national healthcare ecosystems.

KEY MARKET PLAYERS

Some of the companies that are playing a dominating role in the global European Suture Market include

• Ethicon (Johnson & Johnson Services, Inc.)
• Medtronic plc
• Braun Melsungen AG
• Teleflex Incorporated
• Braun Surgical Suture Solutions
• Smith & Nephew plc
• Surgical Specialties Corporation
• KLS Martin Group
• ConMed Corporation
• Lone Star Medical Products, Inc.
• BD (Becton, Dickinson and Company)
• Zimmer Biomet Holdings, Inc.
• Delta Med (Sutures & Devices)
• Fallbrook Medical (Suture Innovations)
• Aspen Surgical Products
• Teleflex (Teleflex Medical OEM)
• Serag-Wiessner GmbH & Co. KG
• Sutures India Pvt. Ltd.
• Medical & Biological Laboratories Co., Ltd.
• Meril Life Sciences Pvt. Ltd.

TOP LEADING PLAYERS IN THE MARKET

• Johnson & Johnson MedTech, through its Ethicon division,n is a leading force in the European suture market, offering a comprehensive portfolio of absorbable and non-absorbable sutures, es including advanced antimicrobial and barbed technologies. The company supplies major hospitals and ambulatory centers across the region with products aligned to EU Medical Devices Regulation standards. Ethicon has strengthened its European presence by expanding its surgical education programs in collaboration with national surgical societies to train clinicians on optimal suture selection and knotless techniques. In recent years, it launched next-generation monofilament sutures with enhanced elasticity for plastic surgery and introduced triclosan-free antimicrobial coatings to meet evolving environmental and safety expectations. Its integration with robotic surgery platforms like Ottava further positions Ethicon at the forefront of precision wound closure in minimally invasive procedures across Europe.
• Braun SE is a Germany-based global medical technology leader with deep roots in the European suture market through its Aesculap division. The company provides a wide range of surgical sutures, including specialty products for cardiovascula,,r neurosurg,ery and ophthalmologyy tailored to European clinical protocols. B. Braun emphasizes sustainability and local manufacturing with its sutures produced in ISO certified facilities in Germany andSpain,n ensuring supply chain resilience and regulatory compliance. Recently, the company enhanced its suture portfolio with bioactive coatings that support tissue regeneratireducereduced inflammation in elderly patients. It also launched digital training modules for surgical residents in partnership with university hospitals in France and Italy to promote standardized wound closure practices.
• Medtronic plc maintains a significant footprint iEuropeanEurope suture market through its Surgical Innovations business, which includes automated suturing and advanced manual suture solutions. The company leverages its expertise in minimally invasive and robotic-assisted surgery to offer integrated suture delivery systems compatible with its energy and stapling platforms. In Europe, Medtronic has expanded its portfolio of barbed sutures for soft tissue approximation in bariatric and gynecological procedures,s where rapid healing and reduced operative time are important. The company recently collaborated with Nordic healthcare systems to implement value-based contracts linking suture performance to postoperative infection rates. Additionally, Medtronic supports European surgical registries with real-world data on suture outcomes, enhancingevidence-basedd adoption.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players in the European suture market focus on regulatory compliance by ensuring full alignment with the EU Medical Devices Regulation, including unique device identification and post market surveillance systems. They invest in advanced material science to develop antimicrobial bioactive and barbed sutures that reduce complications and support faster healing. Companies expand surgical education through partnerships with national associations and academic hospitals to standardize best practices and drive product adoption. Strategic integration with robotic and minimally invasive platforms enhances compatibility and workflow efficiency in modern operating rooms. Additionally, firms pursue sustainability initiatives by optimizing packaging, reducing single-use waste, and developing eco-friendly coatings to meet tightening environmental regulations, particularly in Western Europe.

MARKET SEGMENTATION

This research report on the europe suture market is segmented and sub-segmented into the following categories.

By Product Type

• Suture Threads
• Automated Suturing Devices

By Type

• Monofilament Sutures
• Multifilament Sutures

By Application

• General Surgery
• Cardiovascular Surgery
• Orthopedic Surgery
• Cosmetic & Plastic Surgery
• Gynecological Surgery
• Others

By End User

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Country

• Germany
• United Kingdom
• France
• Italy
• Netherlands
• Rest of Europe